| Term 
 
        | Name 2 direct acting choline esters. |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | bethanechol, carbachol are which type of drugs? |  | Definition 
 
        | direct acting choline esters |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | muscarinic agonist, negligible effect at nicotinic recepts |  | 
        |  | 
        
        | Term 
 
        | Which drug is a muscarinic agonist, with negligible effect at nicotinic receptors? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are the effects of bethanechol? |  | Definition 
 
        | activates M1 - M3 receptors in all peripheral tissues, increased secretion, smooth muscle contraction (except vascular smooth muscle, which relaxes), and changes in heart rate |  | 
        |  | 
        
        | Term 
 
        | clinical applications for bethanechol? |  | Definition 
 
        | postop and neurogenic ileus and urinary retention |  | 
        |  | 
        
        | Term 
 
        | How is bethanechol given? What is its duration? Does it enter the CNS? |  | Definition 
 
        | oral or parenteral, 30 min, no it does not enter the CNS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | excessive parasympathomimetic effects, especially bronchospasm in asthmatics, interactions - additive with other parasympathomimetics |  | 
        |  | 
        
        | Term 
 
        | Name a nonselective muscarinic and nicotonic agonist. What is it used for? |  | Definition 
 
        | carbachol, used topically almost exclusively for glaucoma |  | 
        |  | 
        
        | Term 
 
        | Name the direct acting muscarinic alkaloids or synthetics |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What are pilocarpine and cevimeline? |  | Definition 
 
        | direct acting muscarinic alkaloid and synthetic |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of pilocarpine? |  | Definition 
 
        | muscarinic partial agonist |  | 
        |  | 
        
        | Term 
 
        | What are the effects of pilocarpine? |  | Definition 
 
        | activates M1 - M3 receptors in all peripheral tissues, increased secretion, smooth muscle contraction (except vascular smooth muscle, which relaxes), and changes in heart rate |  | 
        |  | 
        
        | Term 
 
        | What are the clinical applications for pilocarpine? |  | Definition 
 
        | glaucoma, sjogren's syndrome |  | 
        |  | 
        
        | Term 
 
        | Which drug is used for glaucoma and sjogren's syndrome? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How is pilocarpine given? Toxicity? |  | Definition 
 
        | oral lozenge and topical, excessive parasympathomimetic effects, especially bronchospasm in asthmatics, interactions - additive with other parasympathomimetics |  | 
        |  | 
        
        | Term 
 
        | Which drug is used as an oral lozenge and topically? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Cevimeline is selective for which receptor? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | The effects of cevimeline are similar to which other drug? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Which M receptors use Gq -> IP3 and the DAG cascade? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Which M receptors use Gi -> inhibition of cAMP production, activation of K+ channels? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 | 
        |  | 
        
        | Term 
 
        | Which M receptor is present only on nerves? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Where is the M2 receptor located? |  | Definition 
 
        | heart, nerves, smooth muscle |  | 
        |  | 
        
        | Term 
 
        | Which M receptor is present on heart, nerves and smooth muscle? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Where is the M3 receptor located? |  | Definition 
 
        | glands, smooth muscle, endothelium |  | 
        |  | 
        
        | Term 
 
        | Which receptor is present on glands, smooth muscle and endothelium? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | M4 and M5 are present where? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Which M receptors are present in the CNS? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Name the direct acting nicotinic agonists |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | direct acting nicotinic agonist at both Nn and Nm receptors |  | 
        |  | 
        
        | Term 
 
        | How do the nicotinic receptors work? |  | Definition 
 
        | Na+, K+ depolarizing ion channel |  | 
        |  | 
        
        | Term 
 
        | What are the effects of nicotine? |  | Definition 
 
        | activates autonomic postganglionic neurons (both sym and parasym) and skeletal muscle neuromuscular end plates, enters CNS and activates Nn receptors |  | 
        |  | 
        
        | Term 
 
        | which drug activates autonomic postganglionic neurons (both sym and parasym) and skeletal muscle neuromuscular end plates, enters CNS and activates Nn receptors? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | clinical applications for nicotine? |  | Definition 
 
        | medical use in smoking cessation, nonmedical use in smoking and in insecticides |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | increased GI activity, nausea, vomiting, diarrhea acutely, increased BP, high doses cause seizures, long term GI and CV risk factors, additive with CNS stimulants |  | 
        |  | 
        
        | Term 
 
        | Which drug causes increased GI activity, nausea, vomiting, diarrhea acutely, increased BP, high doses cause seizures, long term GI and CV risk factors, and is additive with CNS stimulants? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the MOA of varencicline? |  | Definition 
 
        | selective partial agonist at a4b2 nicotinic recepts, used exclusively for smoking cessation |  | 
        |  | 
        
        | Term 
 
        | Name a short acting cholinesterase inhibitor |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | a short acting cholinesterase inhibitor |  | 
        |  | 
        
        | Term 
 
        | What type of chemical is edrophonium? What is the MOA of edrophonium? |  | Definition 
 
        | it's an alcohol, binds briefly to active site of AchE, and prevents access of Ach |  | 
        |  | 
        
        | Term 
 
        | Which drug binds briefly to active site of AchE, and prevents access of Ach? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | amplifies all actions of Ach, increases parasympathetic activity and somatic neuromuscular transmission |  | 
        |  | 
        
        | Term 
 
        | What is edrophonium used for? |  | Definition 
 
        | dx and acute tx of myasthenia gravis |  | 
        |  | 
        
        | Term 
 
        | What is used for the dx and acute tx of myasthenia gravis? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How is edrophonium given? What kind of molecule is it? Does it enter the CNS? |  | Definition 
 
        | parenteral, quaternary amine, does NOT enter CNS |  | 
        |  | 
        
        | Term 
 
        | Name 3 quaternary amine drugs.  Do they enter the CNS? |  | Definition 
 
        | edrophonium, neostigmine, pyridostigmine, NO does NOT enter CNS |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | parasympathomimetic access, additive with other parasympathomimetics |  | 
        |  | 
        
        | Term 
 
        | Name an intermediate acting cholinesterase inhibitor |  | Definition 
 
        | neostigmine, pyridostigmine (longer acting), physostigmine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | an intermediate-acting cholinesterase inhibitor |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | forms covalent bond with AchE, but hydrolyzed and released |  | 
        |  | 
        
        | Term 
 
        | Which drug forms a covalent bond with AchE, but it is hydrolyzed and released? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is neostigmine used for? |  | Definition 
 
        | MG, postop and neurogenic ileus and urinary retention |  | 
        |  | 
        
        | Term 
 
        | Which drug is used for MG, postop and neurogenic ileus and urinary retention? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How is neostigmine given? What type of amine is it? Does it enter the CNS? |  | Definition 
 
        | oral and parenteral, quaternary amine, NO it does NOT enter the CNS |  | 
        |  | 
        
        | Term 
 
        | How long does pyridostigmine act? What is it used for? |  | Definition 
 
        | 4-6 hrs, slightly longer than neostigmine, used for MG |  | 
        |  | 
        
        | Term 
 
        | What type of drug is physostigmine? What type of molecule is it? Does it enter the CNS? |  | Definition 
 
        | intermediate acting AchE inhibitor, natural alkaloid tertiary amine, YES it enters CNS |  | 
        |  | 
        
        | Term 
 
        | Name an intermediate acting AchE inhibitor that enters the CNS |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | What is the duration of neostigmine? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | a long-acting cholinesterase inhibitor |  | 
        |  | 
        
        | Term 
 
        | What is the MOA of echothiophate? |  | Definition 
 
        | like neostigmine (forms covalent bond) but it is released more slowly |  | 
        |  | 
        
        | Term 
 
        | which drug has an MOA like neostigmine (forms covalent bond) but it is released more slowly? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | clinical applications for echothiophate? |  | Definition 
 
        | obsolete, was used in glaucoma |  | 
        |  | 
        
        | Term 
 
        | which drug is now obsolete but was used for glaucoma? |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | How is echothiophate given? Toxicity? |  | Definition 
 
        | topical only, brow ache, uveitis, blurred vision |  | 
        |  | 
        
        | Term 
 
        | Which drug is given topically only and causes brow ache, uveitis, blurred vision? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | an insecticide that is relatively safe for mammals and birds because it's metabolized by other enzymes to inactive products, some medical use as ectoparasiticide |  | 
        |  | 
        
        | Term 
 
        | which drug is an insecticide that is relatively safe for mammals and birds because it's metabolized by other enzymes to inactive products, and has some medical use as ectoparasiticide? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | insecticide, dangerous for all animals, toxicity important because of agricultural use and exposure of farm workers? |  | 
        |  | 
        
        | Term 
 
        | Which drug is an insecticide, is dangerous for all animals, and has toxicity that's important because of agricultural use and exposure of farm workers? |  | Definition 
 | 
        |  | 
        
        | Term 
 | Definition 
 
        | Sarin, a long acting cholinesterase inhibitor |  | 
        |  | 
        
        | Term 
 
        | Only direct acting agent that is very lipid soluble and used in glaucoma |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Treatment of atropine overdose and glaucoma (because lipid soluble).  Enters the CNS rapidly and has a stimulant effect, which may lead to convulsions |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Antiglaucoma organophosphate |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Associated with an increased incidence of cataracts in patients treated for glaucoma |  | Definition 
 
        | Long acting cholinesterase inhibitors |  | 
        |  | 
        
        | Term 
 
        | Scabicide organophosphate |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Organophosphate anthelmintic agent with long DOA |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Toxicity of organophosphate: |  | Definition 
 
        | DUMBELSS (diarrhea, urination, miosis, bronchoconstriction, excitation of skeletal muscle and CNS, lacrimation, salivation, and sweating) |  | 
        |  | 
        
        | Term 
 
        | The most important cause of acute deaths in cholinesterase inhibitor toxicity |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | The most toxic organophosphate |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | Treatment of choice for organophosphate overdose |  | Definition 
 | 
        |  | 
        
        | Term 
 
        | This agent regenerates active cholinesterase and is a chemical antagonist used to treat organophosphate exposure |  | Definition 
 | 
        |  |